| Entry |
|
|---|
| Name |
Doravirine (JAN/USAN/INN);
Pifeltro (TN) |
|---|
| Product |
|
|---|
| Formula |
C17H11ClF3N5O3
|
|---|
| Exact mass |
425.0503
|
|---|
| Mol weight |
425.7492
|
|---|
| Structure |
|
|---|
| Class |
Antiviral
DG01889 Non-nucleoside reverse transcriptase inhibitor (NNRTI)
|
|---|
| Remark |
| Therapeutic category: | 6250 |
| Product (mixture): | D11396<US> |
|
|---|
| Efficacy |
Antiviral, Reverse transcriptase inhibitor |
|---|
| Disease |
|
|---|
| Target |
RNA-directed DNA polymerase |
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AG Non-nucleoside reverse transcriptase inhibitors
J05AG06 Doravirine
D10624 Doravirine (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Doravirine
D10624 Doravirine (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D10624 Doravirine (JAN/USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10624
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10624
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10624
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10624
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10624
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 29
1 C8x C 14.2557 -16.0257
2 C8y C 14.2557 -17.3764
3 C8x C 15.4254 -18.0516
4 C8y C 16.5951 -17.3764
5 C8x C 16.5951 -16.0257
6 C8y C 15.4254 -15.3504
7 X Cl 15.4254 -13.9997
8 O2a O 17.7648 -18.0516
9 C8y C 18.9346 -17.3764
10 C8y C 20.0898 -18.0434
11 C8x C 21.2596 -17.3683
12 C8x C 21.2597 -16.0176
13 N4y N 20.1044 -15.3505
14 C8y C 18.9347 -16.0257
15 C1d C 20.0898 -19.3941
16 X F 18.7392 -19.3941
17 X F 21.4405 -19.3941
18 X F 20.0898 -20.7447
19 C1b C 20.1044 -13.9998
20 O5x O 17.7650 -15.3504
21 C3b C 13.0717 -18.0599
22 N3a N 11.8872 -18.7438
23 C8y C 21.3168 -13.2998
24 N4y N 22.6234 -13.8818
25 C8y C 23.5807 -12.8191
26 N4x N 22.8658 -11.5802
27 N5x N 21.4666 -11.8773
28 C1a C 22.9857 -15.2341
29 O5x O 24.9330 -13.1814
BOND 31
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 6 7 1
8 4 8 1
9 8 9 1
10 9 10 2
11 10 11 1
12 11 12 2
13 12 13 1
14 13 14 1
15 9 14 1
16 10 15 1
17 15 16 1
18 15 17 1
19 15 18 1
20 13 19 1
21 14 20 2
22 2 21 1
23 21 22 3
24 19 23 1
25 23 24 1
26 24 25 1
27 25 26 1
28 26 27 1
29 23 27 2
30 24 28 1
31 25 29 2
|
|---|
